STOCK TITAN

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

Caribou Biosciences, Inc. (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024. The event will be held from November 14-19, 2024, in Washington, DC.

The poster will present preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance for evaluating CB-010 in the GALLOP Phase 1 clinical trial. This trial focuses on patients with lupus nephritis (LN) and extrarenal lupus (ERL).

The presentation, titled 'Preclinical Analysis of CB-010, an Allogeneic anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE),' will be delivered by Elizabeth Garner, PhD, on November 16, 2024.

Caribou Biosciences, Inc. (Nasdaq: CRBU), una azienda biofarmaceutica in fase clinica specializzata nell'editing genomico CRISPR, ha annunciato che un abstract è stato accettato per una presentazione poster al Convegno 2024 del Collegio Americano di Reumatologia (ACR). L'evento si terrà dal 14 al 19 novembre 2024 a Washington, DC.

Il poster presenterà dati preclinici e elementi chiave del disegno dello studio clinico che hanno supportato l'approvazione del farmaco in fase di indagine (IND) per la valutazione di CB-010 nella sperimentazione clinica di fase 1 GALLOP. Questo studio è incentrato su pazienti con nefrite lupica (LN) e lupus extrarenale (ERL).

La presentazione, intitolata 'Analisi preclinica di CB-010, una terapia cellulare CAR-T anti-CD19 allogenica con knockout di PD-1, per il trattamento di pazienti con lupus eritematoso sistemico refrattario (SLE),' sarà condotta da Elizabeth Garner, PhD, il 16 novembre 2024.

Caribou Biosciences, Inc. (Nasdaq: CRBU), una empresa biofarmacéutica en etapa clínica dedicada a la edición genética CRISPR, anunció que se ha aceptado un resumen para una presentación en póster en el Convergencia 2024 del Colegio Americano de Reumatología (ACR). El evento se llevará a cabo del 14 al 19 de noviembre de 2024 en Washington, DC.

El póster presentará datos preclínicos y elementos clave del diseño del ensayo clínico que respaldaron la aprobación del nuevo medicamento en investigación (IND) para evaluar CB-010 en el ensayo clínico de fase 1 GALLOP. Este ensayo se centra en pacientes con nefritis lúpica (LN) y lupus extrarrenal (ERL).

La presentación, titulada 'Análisis preclínico de CB-010, una terapia con células CAR-T anti-CD19 alogénica con knockout de PD-1, para el tratamiento de pacientes con lupus erithematoso sistémico refractario (SLE),' será impartida por Elizabeth Garner, PhD, el 16 de noviembre de 2024.

Caribou Biosciences, Inc. (Nasdaq: CRBU)는 임상 단계의 CRISPR 유전자 편집 생명공학 회사로서 2024년 미국 류마티스 학회(ACR) 컨버전스에서 포스터 발표를 위한 초록이 수락되었음을 발표했습니다. 이 행사는 2024년 11월 14일부터 19일까지 워싱턴 D.C.에서 열릴 예정입니다.

포스터는 CB-010의 GALLOP 1상 임상시험을 위한 연구용 신약(IND) 승인에 기초하여 의학적 기본 데이터 및 임상 시험 설계의 주요 요소를 제시할 것입니다. 이 시험은 루푸스 신염(LN) 및 외신장 루푸스(ERL) 환자에 초점을 맞추고 있습니다.

'PD-1 녹아웃을 포함한 동종 이식 anti-CD19 CAR-T 세포 치료제인 CB-010의 전임상 분석: 난치성 전신성 루푸스 홍반(SLE) 환자의 치료를 위한'이라는 제목의 발표는 2024년 11월 16일 Elizabeth Garner 박사에 의해 진행될 것입니다.

Caribou Biosciences, Inc. (Nasdaq: CRBU), une entreprise biopharmaceutique en phase clinique spécialisée dans l'édition génomique CRISPR, a annoncé qu'un résumé a été accepté pour une présentation par affichage lors de la Convergence 2024 de l'American College of Rheumatology (ACR). L'événement se tiendra du 14 au 19 novembre 2024 à Washington, D.C.

L'affiche présentera des données précliniques et des éléments clés du design de l'essai clinique qui ont soutenu l'autorisation du médicament expérimental (IND) pour l'évaluation de CB-010 dans l'essai clinique de phase 1 GALLOP. Cet essai se concentre sur les patients atteints de néphrite lupique (LN) et de lupus extrarénal (ERL).

La présentation, intitulée 'Analyse préclinique de CB-010, une thérapie par cellules CAR-T anti-CD19 allogéniques avec knockout de PD-1, pour le traitement des patients atteints de lupus érythémateux systémique réfractaire (SLE),' sera réalisée par Elizabeth Garner, PhD, le 16 novembre 2024.

Caribou Biosciences, Inc. (Nasdaq: CRBU), ein biopharmazeutisches Unternehmen in klinischer Phase, das auf CRISPR-Genom-Editing spezialisiert ist, hat bekannt gegeben, dass ein Abstract für eine Posterpräsentation auf der American College of Rheumatology (ACR) Convergence 2024 akzeptiert wurde. Die Veranstaltung findet vom 14. bis 19. November 2024 in Washington, DC, statt.

Das Poster wird präklinische Daten und zentrale Elemente des Studiendesigns vorstellen, die die Genehmigung des investigational new drug (IND) für die Evaluierung von CB-010 in der GALLOP Phase 1-Studie unterstützt haben. Diese Studie konzentriert sich auf Patienten mit Lupusnephritis (LN) und extrarenalem Lupus (ERL).

Die Präsentation mit dem Titel 'Präklinische Analyse von CB-010, einer allogenen anti-CD19 CAR-T Zelltherapie mit PD-1 Knockout zur Behandlung von Patienten mit refraktärem systemischen Lupus erythematodes (SLE),' wird am 16. November 2024 von Elizabeth Garner, PhD, gehalten.

Positive
  • Abstract accepted for poster presentation at ACR Convergence 2024
  • IND clearance obtained for CB-010 in GALLOP Phase 1 clinical trial
  • Preclinical data supports development of CB-010 for lupus treatment
Negative
  • None.

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC.

The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL). Details of the poster presentation are as follows:

Title: Preclinical Analysis of CB-010, an Allogeneic anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Presenter: Elizabeth Garner, PhD, executive director of T cell therapeutics and translational sciences laboratory, Caribou Biosciences
Date and time: Saturday, November 16, 2024, 10:30 am-12:30 pm EST
Session: B cell biology & targets in autoimmune & inflammatory disease poster
Location: Walter E. Washington Convention Center, Washington, DC
Abstract number: 0018

2024 ACR Convergence abstracts will be published at www.acrabstracts.org and the poster presentation will be available on Caribou’s Scientific Publications webpage on Thursday, November 14, 2024 at 10:00 am EST.

About CB-010
CB-010 is the lead clinical-stage product candidate from Caribou’s allogeneic CAR-T cell therapy platform, and it is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 clinical trial and will be evaluated in patients with lupus nephritis (LN) and extrarenal lupus (ERL) in the GALLOP Phase 1 clinical trial. To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA granted CB-010 Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations for B-NHL and Fast Track designations for both B-NHL and refractory systemic lupus erythematosus (SLE). Additional information on the ANTLER trial (NCT04637763) can be found at clinicaltrials.gov.

About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. The potential for CRISPR systems to edit at unintended genomic sites, known as off-target editing, may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to Caribou’s strategy, plans, and objectives, and expectations regarding its clinical development programs, including its expectations relating to development, regulatory approval, results, and the timing of and updates from its ANTLER Phase 1 clinical trial for CB-010, and its GALLOP Phase 1 clinical trial for CB-010. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of Caribou’s current and future research and development programs, preclinical studies, and clinical trials; and the risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of Caribou’s product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available; the risk that preclinical study results observed will not be borne out in human patients or different conclusions or considerations are reached once additional data have been received and fully evaluated; the ability to obtain key regulatory input and approvals; as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com


FAQ

What is Caribou Biosciences presenting at ACR Convergence 2024?

Caribou Biosciences is presenting preclinical data supporting the development of CB-010 for lupus treatment, including key elements of the clinical trial design for the GALLOP Phase 1 study in patients with lupus nephritis and extrarenal lupus.

When and where is the ACR Convergence 2024 taking place?

The American College of Rheumatology (ACR) Convergence 2024 is scheduled to take place from November 14-19, 2024, in Washington, DC at the Walter E. Washington Convention Center.

What is CB-010 and what is it being developed for by Caribou Biosciences (CRBU)?

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout being developed by Caribou Biosciences for the treatment of patients with refractory Systemic Lupus Erythematosus (SLE), specifically lupus nephritis and extrarenal lupus.

Who will be presenting the poster for Caribou Biosciences (CRBU) at ACR Convergence 2024?

The poster will be presented by Elizabeth Garner, PhD, executive director of T cell therapeutics and translational sciences laboratory at Caribou Biosciences.

Caribou Biosciences, Inc.

NASDAQ:CRBU

CRBU Rankings

CRBU Latest News

CRBU Stock Data

163.45M
80.73M
10.04%
62.54%
8.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BERKELEY